Croda Denmark was formerly Brenntag Biosector (Biosector), acquired in 2019 and for more than 80 years has been dedicated to safe and effective adjuvants for use in human and veterinary vaccines. No other company can match our expertise in this area.
Our site at Frederikssund includes R&D, engineering, production QA/QC, administration, warehouse and distribution:
- World leading adjuvant specialist serving major human and veterinary vaccine producers
- Industry leading R&D capabilities for a strong pipeline of innovative next generation vaccine adjuvants
- Running the only aseptic and GMP certified manufacturing site for adjuvants globally
The combination of a passionate team, adjuvant expertise, industry-leading production facilities and a dedicated global sales network committed to understanding customer needs mean we can better serve our pharmaceutical customers through our classic portfolio and our rich development pipeline. We realise the vaccines and blood products of tomorrow require new and innovative adjuvants, so our R&D department is focused on the next generation of adjuvants.
Croda DenmarkElsenbakken 23
Completed divestment – transitioning to a pure-play Consumer Care and Life Sciences company
Accelerating our transition to a pure-play Consumer Care and Life Sciences company, completion of the divestment of the majority of our Performance Technologies and Industrial Chemicals businesses to...Read more
Launch of first report on biotechnology opportunities in the personal care market
27 September 2022: The “Biotechnology: personal care market report” is the first in a series from Croda which aim to help other forward-thinking companies leverage the opportunities offered by...Read more
UK Government to support expansion of Croda's lipid systems manufacturing facility
31 March 2022: This investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines.Read more